⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PVLA News
Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
globenewswire.com
PVLA
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
globenewswire.com
PVLA
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
globenewswire.com
PVLA
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
PVLA
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
globenewswire.com
PVLA
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Form 8-K
sec.gov
PVLA